Affordable Access

deepdyve-link
Publisher Website

[Therapy of herpes zoster and postherpetic neuralgia].

Authors
  • Hüning, S1
  • von Dücker, L2
  • Kohl, W K3
  • Nashan, D4
  • 1 Hautklinik, Klinikum Dortmund gGmbH, Beurhausstr. 40, 44137, Dortmund, Deutschland. [email protected]
  • 2 Klinik für Dermatologie, Allergologie und Venerologie, Universität zu Lübeck, Lübeck, Deutschland.
  • 3 Klinik für Naturheilkunde und integrative Medizin, Evang. Kliniken Essen-Mitte, Essen, Deutschland.
  • 4 Hautklinik, Klinikum Dortmund gGmbH, Beurhausstr. 40, 44137, Dortmund, Deutschland.
Type
Published Article
Journal
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
Publication Date
Aug 01, 2019
Volume
70
Issue
8
Pages
645–656
Identifiers
DOI: 10.1007/s00105-019-4446-0
PMID: 31270550
Source
Medline
Keywords
Language
German
License
Unknown

Abstract

Herpes zoster (HZ) is caused by the reactivation of varicella zoster virus. The incidence of herpes zoster and associated problems increases with age. With a life-long prevalence of 30%, every second 85-year-old person experiences HZ once in his lifetime. Three therapeutic columns are based on antiviral, topical and analgetic therapies. An extreme handicap is acute and persistent pain which can develop into postherpetic neuralgia (PHN). Those pain symptoms are predominantly neuropathic. The management of acute and chronic manifestation of pain may be challenging. HZ vaccination represents a substantial improvement in terms of prevention of herpes zoster and reduction of long-term complications, such as PHN. The permanent vaccination commission of the Robert Koch Institute recommends vaccination with dead virus for all persons over the age of 60 years. Risk groups like immunosuppressed patients are advised to be vaccinated starting at the age of 50 years.

Report this publication

Statistics

Seen <100 times